The abstract is read at the publisher; the summary is JClub's.
Long-acting cabotegravir plus long-acting rilpivirine maintained virologic suppression through week 96 in 144 virologically suppressed adolescents, with no confirmed failures and 24% grade ≥3 adverse events.
- Why it matters: Long-term safety, acceptability, antiviral activity, and drug exposure are needed for adolescents using injectable cabotegravir plus rilpivirine, beyond earlier week 24/48 evidence.
- What they did: In a single-arm phase 1/2 trial, adolescents aged 12–17 years (≥35 kg) switched from oral ART to cabotegravir/rilpivirine injections every 8 weeks through week 96, after oral lead-in, with safety and pharmacokinetics measured through 96 weeks.
- The result: By week 96, 35/144 had grade 3+ adverse events and 3/144 had grade 3+ drug-related events; median week 96 troughs were 2·96 μg/mL for cabotegravir and 89·5 ng/mL for rilpivirine, and ≥97% preferred injections.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.